Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class. The post Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion appeared first on Investor's Business Daily.
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
The post Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion appeared first on Investor's Business Daily.